New hope for MELAS: Long-Term safety trial of zagociguat begins
NCT ID NCT06961344
First seen Nov 01, 2025 · Last updated May 02, 2026 · Updated 22 times
Summary
This study looks at the long-term safety of a daily tablet called zagociguat in people with MELAS, a rare genetic disease that affects energy production and can cause strokes. About 44 participants who finished a previous study will take the drug for an extended period, with clinic visits every 3 to 6 months. The goal is to monitor any side effects and see if the drug remains safe over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MITOCHONDRIAL ENCEPHALOPATHY, LACTIC ACIDOSIS AND STROKE-LIKE EPISODES (MELAS SYNDROME) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Akron Children's Hospital
Akron, Ohio, 44308, United States
-
Baylor College of Medicine
Houston, Texas, 77030, United States
-
Children's Hospital of Colorado
Aurora, Colorado, 80045, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
LMU Klinikum, Friedrich-Baur-Institute, Department of Neurology
Munich, 80336, Germany
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mount Sinai - Ichan School of Medicine
New York, New York, 10029, United States
-
Neurologic Institute Carlo Besta of Milan
Milan, 20133, Italy
-
Neuroscience Research Australia
Sydney, New South Wales, NSW 2031, Australia
-
Rare Disease Research
Atlanta, Georgia, 30329, United States
-
Royal Melbourne Hospital
Melbourne, Victoria, 3052, Australia
-
The Newcastle upon Tyne NHS Foundation Trust
Newcastle upon Tyne, NE14LP, United Kingdom
-
UC San Diego - Altman Clinical and Translational Research Institute
La Jolla, California, 92037, United States
-
UT Health Houston
Houston, Texas, 77030, United States
-
University College London Hospital. The National Hospital for Neurology and Neurosurgery, Centre for Neuromuscular Diseases
London, WC1N 3BG, United Kingdom
Conditions
Explore the condition pages connected to this study.